GlaxoSmithKline PLC carved off more of its non-core OTC brands with the sale of North American rights to five derma lines to Crown Laboratories Inc., which is carving out market share across skin care categories.
In addition to further narrowing it consumer health focus, GSK's sale of Canada, Mexico and US distribution rights for PanOxyl daily acne wash and four other brands generates cash to help pay for its recently announced $5.1bn acquisition of oncology drug firm Tesaro Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?